logo
Stop Using, Start Itching: FDA Flags Risk Tied to Popular Allergy Med Zyrtec

Stop Using, Start Itching: FDA Flags Risk Tied to Popular Allergy Med Zyrtec

Gizmodo5 days ago

Two common anti-allergy medications can leave you feeling scratchier than ever. The Food and Drug Administration is warning that stopping long-term use of cetirizine and levocetirizine can, in rare cases, cause intense itchiness.
The FDA issued its warning earlier this month. Over the past decade, the agency has received hundreds of reports of people experiencing severe—sometimes 'debilitating'—itching after going off the medications. Though it appears to be a rare complication, the FDA is also requiring manufacturers to mention the side effect in the labeling of these drugs.
'The underlying mechanism for this risk is unknown, but our evaluation supports a causal relationship between stopping cetirizine or levocetirizine and pruritus,' the FDA stated in its Drug Safety Communication about the products.
Cetirizine and levocetirizine are both antihistamine drugs that have been around for a while. The former was first approved as the prescription drug Zyrtec in 1995, while levocetirizine was approved as Xyzal in 2007. Though the drugs can still be prescribed, they're also now widely available over-the-counter to treat hay fever and other allergy symptoms.
As useful and safe as these drugs have been for millions of people, whispers of this side effect have been circulating for years. A 2019 study identified potential cases of severe pruritus (itching) related to cetirizine withdrawal dating back to at least 2008, for instance, while a 2016 study reported similar cases in the Netherlands tied to levocetirizine; users have also detailed their unbearable experiences trying to quit these drugs on Reddit and other social media platforms long before the FDA stepped in. While it's possible some people may have had a return of allergy symptoms once they stopped taking these drugs, people commonly reported itching that hadn't existed before or to a degree previously never experienced.
The FDA identified 209 cases worldwide (197 in the U.S.) of new-onset pruritus after cetirizine/levocetirizine withdrawal between April 2017 and July 2023. Most people had taken the medications for over three months, often years, though cases could also occur after only one month of continuous use. Sufferers typically complained of widespread itching that required medical intervention; in some cases, the itching was so severe that it left people bedridden or even led to thoughts of suicide or self-harm.
The silver lining is that this side effect seems to be rare overall. The FDA notes that about 100 million prescriptions or OTC purchases of both drugs combined were made in 2022. People with the side effect aren't necessarily doomed to itch forever, either. The FDA found that 90% of people who restarted their medication resolved their itching, for instance, and about one-third of people were able to avoid a new bout of itching if they slowly weaned off the drug once restarting. Some people have also reported relief after taking a short course of corticosteroids.
Still, if you're a longtime user of these drugs, this is certainly something to be aware of in case you ever decide to stop. People planning to take these drugs long term should also discuss the benefits and risks of doing so with their doctor, the FDA said, 'who can provide advice based on your personal needs.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

I Thought I Was Washing My Bath Towels Often Enough. I Was Dead Wrong
I Thought I Was Washing My Bath Towels Often Enough. I Was Dead Wrong

CNET

time18 minutes ago

  • CNET

I Thought I Was Washing My Bath Towels Often Enough. I Was Dead Wrong

When it comes to cleaning our homes, bathrooms are at the top of the list. While we often clean the obvious parts of the bathroom, it's easy to overlook less visible dirty items -- like bath towels. Even though your bathroom towels may look clean -- after all, they're usually just drying off clean parts of your body -- they could be holding massive amounts of bacteria and germs. I'm often guilty of ignoring my bath towels. As long as they're dry and back in place, I rarely give them a second thought. But to keep myself and my housemates healthy, I'll make a point to wash them more regularly. Learn how often you should wash your bath towels to keep them in tip-top shape and the best temperature for getting the cleanest. Why do you need to clean your bath towels so often? When you dry off with towels, they get moist. This porous, damp environment is the perfect breeding ground for bacteria. A common bath towel can have yeast, mold and E. coli growing on it without you ever knowing it. Gross, right? Regular washing prevents bacteria from growing. LG's WashTower functions as one combined washer and dryer unit. LG When should you reuse or wash bathroom towels? Consumer Reports says that under normal circumstances, a towel can be used three or four times before it needs to be washed. That's "times" not "days." If you have many family members using a towel (like hand towels), it needs to be washed on the third or fourth use. The condition of the person using the towel matters, too. If they're sick, toss it in the laundry after one use. If it's flu season, it's best for every family member to have their own towel -- even if they aren't exhibiting symptoms -- to prevent the potential spread of germs. How often you wash towels also depends on how they're dried after usage. If towels find themselves on the floor, the lack of air circulation will cause bacteria to grow quickly. To prolong the life of your towel, be sure to place damp towels on a towel rack. Better yet, crack open a window or turn on the fan to reduce moisture in the room. Supercharge your dryer by cleaning its vent Supercharge your dryer by cleaning its vent Click to unmute Video Player is loading. Play Video Pause Skip Backward Skip Forward Next playlist item Unmute Current Time 0:04 / Duration 1:37 Loaded : 18.39% 0:04 Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 1:33 Share Fullscreen This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Opacity Opaque Semi-Transparent Text Background Color Black White Red Green Blue Yellow Magenta Cyan Opacity Opaque Semi-Transparent Transparent Caption Area Background Color Black White Red Green Blue Yellow Magenta Cyan Opacity Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Drop shadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset Done Close Modal Dialog End of dialog window. Close Modal Dialog This is a modal window. This modal can be closed by pressing the Escape key or activating the close button. Close Modal Dialog This is a modal window. This modal can be closed by pressing the Escape key or activating the close button. Supercharge your dryer by cleaning its vent What temperature is best for washing bath towels? The Infection Control department of Mid-Western Regional Hospital of Ennis, Ireland, recommends washing towels in water that is at least 140 degrees Fahrenheit (60 degrees Celsius) or more to kill bacteria. So if you have a sanitize mode on your washing machine, use it. If not, you may consider raising the temperature on your water heater while washing that load. Be sure young children are supervised around sinks, tubs and showers while you do laundry, though, to prevent burns. And, before you reach for the fabric softener, don't. Fabric softener leaves residue on towels that makes them less absorbent.

Ecosense Supports Breath of Hope Ohio Gala to Advance Lung Cancer Research
Ecosense Supports Breath of Hope Ohio Gala to Advance Lung Cancer Research

Associated Press

time25 minutes ago

  • Associated Press

Ecosense Supports Breath of Hope Ohio Gala to Advance Lung Cancer Research

San Jose, CA - June 5, 2025 - The 2025 Breath of Hope Ohio Gala received continued annual support from Ecosense, the leading innovator in radon detection technology, on Saturday, May 17, 2025. The annual event generated $175,000 for The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) to fund the development of innovative lung cancer research. Ecosense donated its award-winning smart radon monitoring devices to the silent auction at the event as part of its dedication to community health. The donations from Ecosense supported Breath of Hope Ohio, which operates under the OSUCCC – James, to provide hope and support to lung cancer patients and fund research for lung cancer cures. Ecosense feels privileged to support the Breath of Hope Ohio Gala, according to Insoo Park, who serves as both Founder and CEO of the company. 'Here at Ecosense, we are dedicated to using scientific innovation to create healthier environments. Our organization supports radon detection as an essential tool for lung cancer prevention because it enables early diagnosis. We are proud to align with the Gala's powerful message: 'If you have lungs, you're at risk.' Of course, individuals who smoke face higher risks, but those who don't smoke must also be aware of other environmental factors, like radon gas, which is a leading cause of lung cancer among non-smokers.' The naturally occurring radioactive radon gas is the second primary lung cancer risk factor. The radon detection technology from Ecosense provides instant, accurate monitoring solutions that are both simple to operate and deliver reliable results to consumers and professionals. The Ohio State University Foundation manages all donations to the Breath of Hope Ohio program so that every dollar supports meaningful cancer research. Ecosense joins a developing network of organizations that work together to improve lung cancer results through awareness initiatives and innovative solutions, and direct action. For press inquiries or additional information, please contact Thomas Mustac, Otter PR - Senior Publicist, at [email protected]. About Breath of Hope Ohio Breath of Hope Ohio is dedicated to raising funds to support innovative research necessary for a cure for lung cancer. Dollars raised directly support recruiting talented researchers and advancing lung cancer research at the Thoracic Oncology Department at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) for increasing awareness, driving research, finding new treatments and ultimately, a cure. The 'Breath of Hope Ohio' Gala was started by Sandy and Mark Lomeo after Mark was diagnosed with lung cancer in April 2014. They were surprised to discover the lack of funding for lung cancer as compared to many other types of cancer. They decided to raise money by hosting an annual gala where researchers, caregivers, patients and professionals could come together, learn from one another and build community. Visit the Breath of Hope Ohio website to donate and to learn more about our mission. Media Contact: Email Mary Ellen Fiorino at [email protected] with media questions. For general questions about Breath of Hope Ohio, please contact Katie Hughes at [email protected] About Ecosense Ecosense operates from the center of Silicon Valley as a reliable company that provides professional and consumer radon detection and monitoring solutions. Ecosense uses patented ion chamber technology to provide immediate, accurate readings, which take only minutes instead of days. The EcoQube smart radon monitor from Ecosense received recognition as one of TIME's 100 Best Inventions of 2021 and earned a CES Innovation Awards Honoree status. The University of Michigan and Kansas State University validated Ecosense's technology. At the same time, the 2023 Canadian National Radon Proficiency Program (C-NRPP) study identified the company as the industry leader in detection accuracy. Media Contact Company Name: Otter PR Contact Person: Thomas Mustac Email: Send Email Phone: 3478049500 Address:100 E Pine St Suite 110 City: Orlando State: Florida Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Ecosense Supports Breath of Hope Ohio Gala to Advance Lung Cancer Research

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files ANDA for Preservative-Free IV Ketamine
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files ANDA for Preservative-Free IV Ketamine

Associated Press

time25 minutes ago

  • Associated Press

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files ANDA for Preservative-Free IV Ketamine

IBN published this article, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - June 5, 2025 ( NEWMEDIAWIRE ) - NRx Pharmaceuticals (NASDAQ: NRXP), has submitted an Abbreviated New Drug Application (ANDA) to the FDA for NRX-100, its preservative-free intravenous ketamine formulation aimed at approved indications such as anesthesia and pain management. With the U.S. ketamine market valued at $750 million and global demand projected to reach $3.35 billion by 2034, the company is seeking priority review amid an ongoing national shortage. NRx also plans to petition the FDA to mandate preservative-free ketamine formulations, citing safety concerns over benzethonium chloride. This filing complements its broader strategy to expand ketamine's label to include treatment for suicidal depression, backed by clinical data from more than 1,000 patients. To view the full press release, visit About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI. NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality. NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: The latest news and updates relating to NRXP are available in the company's newsroom at Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading 'Risk Factors' discussed under the caption 'Item 1A. Risk Factors' in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption 'Item 1A. Risk Factors' in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. About IBN IBN is a cutting-edge communications and digital engagement platform providing tailored Platform Solutions for select private and public companies. Over the course of 19+ years, IBN has introduced over 70 investor facing brands to the investment public and amassed a collective audience of millions of social media followers. These distinctive investor brands amplify recognition and reach as well as help fulfill the unique needs of our rapidly growing and diverse base of client-partners. IBN will continue to expand our branded network of influential properties as well as leverage the energy and experience of our team of professionals to best serve our clients. IBN's Platform Solutions provide access to: (1) our Dynamic Brand Portfolio (DBP) through 70+ investor facing brands; (2) article and editorial syndication to 5,000+ news outlets; (3) full-scale distribution to a growing Social Media Network (SMN) ; (4) a network of wire solutions via InvestorWire to effectively reach target markets and demographics; (5) Press Release Enhancement to ensure accuracy and impact; (6) a full array of corporate communications solutions; and (7) total news coverage solutions. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Media Contact IBN Los Angeles, California 310.299.1717 Office [email protected] View the original release on

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store